Pompano Beach, FL, Oct. 01, 2018 — BioStem Life Sciences (“Life Sciences” or the “Company”), a wholly owned subsidiary of BioStem Technologies, Inc. (OTC PINK: BSEM), a Company focused on the development of the highest quality placental-based amniotic tissue products, whose mission is to create a new paradigm of healthcare, using breakthrough therapies that treat patients who otherwise are without effective treatment options, announced today that it has entered the market with four placental-derived tissue products for multiple indications within the ophthalmology, orthopedic and advanced wound care markets. [Read more…]
Ncardia and Nanion Technologies Align Forces to Accelerate Drug Discovery & Development
Major news broke in the iPSC sector last week when Ncardia (Cologne, Germany) and Nanion Technologies (Munich, Germany) signed a joint marketing and sales promotion agreement. Under the terms of partnership, customers of the companies will get access to high-performance instrument platforms from Nanion, coupled with Ncardia’s portfolio of hiPSC-derived cardiac cell types and assay services. [Read more…]
Your Ultimate Guide to Cell and Gene Therapy Conferences
Cell and gene therapy conferences have been rapidly multiplying over the past decade. This article is your ultimate guide to cell and gene therapy conferences worldwide. These conferences include presentations on stem cells, CAR-T, exosomes, and other types of cell and gene therapy applications.
Our goal is for this to be a comprehensive guide to cell and gene therapy events worldwide, so we welcome new additions in the comments below. [Read more…]
Maximum Signaling for Maximum Regeneration – Using Four Material RICHGEN Flowable Allograft
It’s the newest breakthrough in regenerative medicine: Using cytokine, growth factors and intracellular miRNA signaling with bio-scaffold from the extra cellular matrix components utilizing minimally-manipulated placental tissue materials. It is NOT about cell counts. It is about increasing the amplitude of signaling from the initial and continued inflammatory (injury) to the individual cell signaling pathway utilized to repair or regenerate the cellular structure that has been injured, diseased, or traumatized. [Read more…]
Interview with Kyle Cetrulo, CEO of AuxoCell Laboratories
This is an interview with Kyle Cetrulo, Founder and CEO of AuxoCell Laboratories, a company specializing in solid tissue processing using its AC:Px System. In addition to heading Auxocell and being a thought-leader on perinatal stem cells, Kyle is an organizer for the upcoming 2nd Annual Perinatal Stem Cell Society Conference that will take place each March in Aspen, CO.
[Read more…]
- « Previous Page
- 1
- …
- 109
- 110
- 111
- 112
- 113
- …
- 201
- Next Page »